Filtered By:
Condition: Headache
Nutrition: Vitamin A

This page shows you your search results in order of date.

Order by Relevance | Date

Total 19 results found since Jan 2013.

E-110 Bilateral hypoplasia of the internal carotid artery (ICA) and intracranial vasculopathy with 'moyamoya phenomenon in association with alagille syndrome
ConclusionThe educational value of our case lies not only in the rarity of the condition but also in the uniqueness of patient presentation. It would be a helpful addition to the existing literature on rare genetic syndromes with cerebral vasculature involvement.Abstract E-110 Figure 1Disclosures H. Shakeel: None. J. Gandhi: None. R. Singh: None. A. Graziano: None. R. Cerejo: None.
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Shakeel, H., Gandhi, J., Singh, R., Graziano, A., Cerejo, R. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

Rational clinical approach to transient ischaemic attack, stroke and associated mimics: A retrospective cohort study
CONCLUSIONS: The present study demonstrated that specific clinical features and risk factors were associated with the final diagnosis at TIA clinic. These clinical features may assist with diagnosis of TIA in centres without access to a vascular neurologist.PMID:37190670 | DOI:10.1111/1742-6723.14238
Source: Atherosclerosis - May 16, 2023 Category: Cardiology Authors: Rudy Goh Stephen Bacchi Lydia Lam Timothy Kleinig Jim Jannes Source Type: research

Ischemic stroke is a potential complication of uncontrolled inflammation in mevalonate kinase deficiency – A case report
Mevalonate kinase deficiency (MKD) is an autosomal recessive monogenic autoinflammatory disease (AID) characterized by recurrent antigen-independent systemic inflammation attacks, interleukin-1beta hypersecretion, fever and pain.1 Neurological manifestations include headaches, fatigue, retinal dystrophy, ataxia and development delay.2
Source: Journal of Stroke and Cerebrovascular Diseases - October 12, 2022 Category: Neurology Authors: Justine Blais, Didier Bonneville-Roussy, Hannah Laure Elfassy, Sylvain Lanthier Tags: Case Report Source Type: research

What Causes Sudden Vision Loss?
Discussion Vision loss, whether chronic or acute, is distressing at any time for patients and families. Prompt evaluation and treatment are important as maintenance of any acuity and light or movement is considered paramount. Most vision loss is due to chronic problems and aging issues but the differential diagnosis is broad. For any age, but especially children, uncorrected refractive errors can cause problems in not only in childhood but throughout someone’s lifetime. Visual impairment for distance vision is considered mild if worse than 6/12 in meters = 20/40 in feet or 0.3 LogMAR and for moderate impairment is 6/...
Source: PediatricEducation.org - September 5, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Development of cognition decline in non-acute symptomatic patients with cerebral small vessel disease: Non-Acute Symptomatic Cerebral Ischemia Registration study (NASCIR)--rationale and protocol for a prospective multicentre observational study
This study aims to investigate risk factors, clinical course, cerebral and retinal imaging changes, proteomics features of non-symptomatic ischaemia symptomatic patients with cognitive decline. Methods and analysis The Non-Acute Symptomatic Cerebral Ischemia Registration study is a multicentre, registry-based, prospective observational study, is designed to investigate the cognitive decline in non-acute ischaemia symptomatic patients. We will recruit 500 non-acute ischaemia symptomatic patients from four tertiary hospitals in China. For this study, non-acute ischaemia symptoms will be defined as headaches, dizziness and m...
Source: BMJ Open - February 22, 2022 Category: General Medicine Authors: Zhang, S., Wang, Z., Liu, P., Tuo, Q., Cheng, Y., Xu, M., Wu, Q., Lei, P., Dai, L., Kwapong, W. R., Tan, M., Liu, M. Tags: Open access, Neurology Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Recurrent Vertebrobasilar Strokes Associated With Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE)
Conclusions: This case illustrates the importance of careful evaluation and high clinical suspicion for this entity when dealing with patients with new-onset headache or stroke associated with visual impairment. Proper ophthalmologic evaluation is important so that adequate therapy is established.
Source: The Neurologist - September 1, 2020 Category: Neurology Tags: Case Report/Case Series Source Type: research

Migraine Aura: Updates in Pathophysiology and Management
AbstractPurpose of ReviewTo provide an updated review of the pathophysiology, diagnosis, and management of migraine with aura.Recent FindingsThalamic and other subcortical regions may play a role in the pathophysiology of migraine. There is inter-patient and intra-patient attack variability in the characteristics of typical aura especially visual aura symptoms. Migraine with brainstem aura may originate cortically. Migraine with retinal aura may be associated with structural and functional changes in the retina.SummaryAlthough cortical spreading depression (CSD) continues to be the predominant theory surrounding the pathop...
Source: Current Neurology and Neuroscience Reports - May 18, 2020 Category: Neuroscience Source Type: research

Migraine Aura: Updates in Pathophysiology and Management.
Abstract PURPOSE OF REVIEW: To provide an updated review of the pathophysiology, diagnosis, and management of migraine with aura. RECENT FINDINGS: Thalamic and other subcortical regions may play a role in the pathophysiology of migraine. There is inter-patient and intra-patient attack variability in the characteristics of typical aura especially visual aura symptoms. Migraine with brainstem aura may originate cortically. Migraine with retinal aura may be associated with structural and functional changes in the retina. Although cortical spreading depression (CSD) continues to be the predominant theory surround...
Source: Epilepsy Curr - May 18, 2020 Category: Neurology Authors: Lai J, Dilli E Tags: Curr Neurol Neurosci Rep Source Type: research

Intrathecal baclofen as emergency treatment alleviates severe intractable autonomic dysreflexia in cervical spinal cord injury.
Conclusion/Clinical Relevance: The case demonstrated that refractory AD could be managed with ITB in an emergency. PMID: 31815605 [PubMed - as supplied by publisher]
Source: Journal of Spinal Cord Medicine - December 10, 2019 Category: Orthopaedics Tags: J Spinal Cord Med Source Type: research

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news